Document is current
Any future updates will be listed below
-
Authors
- License Information
-
More Information
Article History
Received: 13 April 2023
Accepted: 7 July 2023
First Online: 2 August 2023
Declarations
:
: Not applicable.
: All authors read and approved the final manuscript.
: MP and TM declare no financial or non-financial competing interests regarding this review. LS has conducted consultancy/is member of the board for Biogen, Roche, Novartis, Sarepta, Santhera, Dyne, Pfizer, RegenexBio, Dynacure, Audentes, Sysnav, Illumina, Zentech, Evox, Affinia and PTC.
